Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen executed an exclusive license with Roots Pharmaceutical and partner Al-Dhow International Holding for OCU400, its modifier gene therapy for retinitis pigmentosa, across the Middle East and North Africa. Ocugen receives an upfront fee and development milestones up to $4 million, sales milestones up to $255 million, and 22% royalties on MENA net sales, while retaining commercial manufacturing and supply of OCU400. The deal extends global access for OCU400 into a region where RP prevalence is estimated 10-20x higher than the U.S.
Key figures
- Deal Value Usd
- $255 million in potential sales milestones plus up to $4 million upfront and initial development payments
- Royalty rate
- 22% of net sales
- Sales milestones
- $255 million
- Upfront and development payments
- $4 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.